SPE Capital and Proparco in Moroccan pharma deal

SPE Capital Partners has acquired Saham Pharma - an antibiotics manufacturer and hospital provider in Morocco - alongside Proparco as a minority investor. 

The deal is the fourth transaction executed through SPE AIF I, a $200 million Africa-focused private equity fund closed in 2019.  It is also the second direct equity investment of Proparco within the healthcare sector of Morocco, following the investment in ODM group in 2018.

Saham Pharma, founded in 2011 after Saham Group’s acquisition of GlaxoSmithKline’s beta-lactams production site in Morocco and led by Younous Elalamy, is among the fastest growing pharmaceuticals companies in Morocco.